**PP2A promotes apoptosis and facilitates docetaxel sensitivity via the PP2A/p-eIF4B/XIAP signaling pathway in prostate cancer**

SIWEN YIN, YONG CHEN, HANG TONG, TINGHAO LI, ZIJIA QIN, JUNLONG ZHU and WEIYANG HE

Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China

Received June 23, 2021; Accepted November 10, 2021

DOI: 10.3892/ol.2022.13221

**Abstract.** Serine/threonine protein phosphatase 2A (PP2A) is a protein that has a wide range of biological functions. As prostate cancer progresses from hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC), the expression level of PP2A has been found to decrease. The present study aimed to determine the roles that PP2A may play in prostate cancer and its association with the downstream factor, X-linked inhibitor of apoptosis (XIAP). First, the mRNA and protein expression levels of PP2A in LNCaP, DU145 and PC-3 prostate cancer cell lines were measured. Next, the population of PP2A heterodimers was increased using a PP2A agonist, DT061, in the DU145 and PC-3 cell lines. PP2A expression was then knocked down in the LNCaP cell line. Western blot analysis was performed to determine the association between PP2A, phosphorylated (p)-eukaryotic initiation factor 4B (eIF4B) and XIAP. The results revealed that following the increase in PP2A expression, the DU145 and PC-3 cell lines were more sensitive to docetaxel according to Cell Counting Kit-8 assays and had an increased apoptotic rate as assessed by flow cytometry. Conversely, following the transfection of small interfering (si)PP2A into the LNCaP cell line, the sensitivity to docetaxel decreased, as well as the apoptotic rate. In addition, following treatment with the PP2A agonist, DT061, PP2A expression was found to be significantly upregulated, while p-eIF4B and XIAP protein expression levels were significantly downregulated. By contrast, following the transfection of siPP2A into the LNCaP cell line, PP2A protein expression levels were found to be downregulated, while p-eIF4B and XIAP expression levels were significantly upregulated. In conclusion, by affecting the downstream factor XIAP, PP2A may play a key role in promoting apoptosis and facilitating docetaxel sensitivity in prostate cancer cell lines.

**Introduction**

Prostate cancer is a common type of cancer in men and the second leading cause of malignant tumor-related mortality. In the United States, an estimated 26,120 deaths were attributed to prostate cancer in 2016 (1). Androgen deprivation therapy (ADT) has been shown to be an effective treatment for prostate cancer, proving indispensable for advanced-stage prostate cancer (2-4). However, the majority of prostate cancer cases develop into castration-resistant prostate cancer (CRPC) following ADT within 2 years (5,6), despite the circulating testosterone levels being decreased to ‘castrate level’. CRPC is associated with poor survival rates, and currently, no effective methods exist to prevent progression (7). Therefore, determining the molecular mechanism that promotes CRPC and identifying novel targets for CRPC treatment are important.

Serine/threonine protein phosphatase 2A (PP2A) is a tumor-suppressive factor that has been discovered to participate in numerous signaling pathways, including PI3K/Akt/mTOR, Wnt/β-catenin and c-Myc pathways (8). It was previously reported that the deregulation of PP2A and its regulatory subunits was commonly observed in breast cancer, and such an event was associated with an unfavorable outcome (9). The subsequent restoration of PP2A, due to its functional deficiency in colorectal cancer, was also revealed to enhance the patient response to chemotherapy (10). The expression levels of PP2A have been found to be downregulated in various types of cancer, such as breast (9), colorectal (10) and lung cancer (11), as well as acute myeloid leukemia (12); however, to the best of our knowledge, few studies have reported the changes in the expression levels during prostate cancer tumorigenesis and its effect on apoptosis and chemoresistance. Therefore, determining the effect of PP2A on the development of prostate cancer is of great significance.

X-linked inhibitor of apoptosis (XIAP) is an antiapoptotic factor whose expression has been found to be upregulated in various types of cancer, such as bladder cancer (13), renal cell carcinoma (14) and acute myeloid leukemia (15). The upregulated expression of XIAP was reported in ovarian carcinoma and esophageal carcinoma cell lines, which were found to be insensitive to chemotherapy (16,17). A previous study also demonstrated that the expression levels of XIAP were markedly upregulated in CRPC tissues and cells compared with those in androgen-sensitive tissues and cells (18). PP2A participates in the cell cycle and...
apoptosis (19). Previous research revealed that dephosphorylation of eukaryotic initiation factor 4B (eIF4B) at serine 406 was mediated by PP2A (20). In addition, another study revealed that Pim-2 proto-oncogene serine/threonine kinase (Pim-2) was upregulated in prostate cancer, and suggested that the Pim-2/eIF4B/XIAP signaling pathway may participate in the progression of prostate cancer (21). Furthermore, Pim-2 was discovered to directly phosphorylate eIF4B within the PP2A signaling pathway and the antiapoptotic effect of PP2A are of critical importance. The present study investigated whether restoration of PP2A promotes apoptosis and facilitates docetaxel sensitivity via the PP2A/p-eIF4B/XIAP signaling pathway in prostate cancer.

Materials and methods

Cell culture and treatment. The human prostate cancer cell line, LNCaP, was purchased from Shanghai Biowing Applied Biotechnology Co., Ltd. The DU145 and PC-3 cell lines were purchased from Shanghai Zhong Qiao Xin Zhou Biotechnology Co., Ltd. The LNCaP cell line was cultured in RPMI-1640 medium (Corning, Inc.) and supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.). Subsequent experimentation was performed at 37˚C in a humidified incubator with 5% CO2.

The DU145 and PC-3 cell lines were cultured in Eagle's Minimum Essential Medium (cat. no. ZQ-301; Shanghai Zhong Qiao Xin Zhou Biotechnology Co., Ltd.), supplemented with Earle's salts, L-glutamine, non-essential amino acids, NaHCO3, 10% FBS and 1% penicillin-streptomycin. All the cell lines were maintained at 37˚C in a humidified incubator with 5% CO2. Trypsin was used for cell dissociation (HyClone; Cytiva).

To increase the expression level of PP2A, an agonist of PP2A, DT061 (10 µmol/l; cat. no. HY-B0011; MedChemExpress), was used to treat the DU145 and PC-3 cell lines. DT061 was dissolved in DMSO (10 µmol/l). The control group contained cells treated with DMSO only. All the cell lines were maintained at 37˚C in a humidified incubator with 5% CO2 for 48 h. The cells were also treated with increasing concentrations of docetaxel (0.00, 0.05, 0.50, 1.00, 2.00, 5.00, 50.00, 200.00 and 500.00 nM; cat. no. HY-B0011; MedChemExpress) at 37˚C for 48 h.

Cell transfection. Cell transfection was performed at 37˚C for 6 h using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). Subsequent experimentation was performed 48 h after transfection, according to the manufacturer's protocol. Briefly, the LNCaP cell line was seeded into six-well plates, at a density of 1.2x105 cells/well, and upon reaching 65-70% confluence, the medium was changed to 2 ml RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.), supplemented with 5 µl Lipofectamine 2000 reagent and 5 µl (20 µl) small interfering (si)RNA. The siRNAs used, which were purchased from Shanghai GenePharma Co., Ltd. (cat. no. A10001), were as follows: siPP2A-2 (siRNA1), 5'-CAC CGA AUU UAUUGG AAAUTT-3'; siPP2A-3 (siRNA2), 5'-GGGCAUUGUACUUCUGGAATT-3'; siPP2A-3 (siRNA3), 5'-GACCUCUACUGCUACUACATT-3'; and si-negative control (NC), 5'-UUCUCGAAACGUGUCAGUTT 3'. The siRNA used in the cell transfection was siPP2A-2 (siRNA2). The NC siRNA used was a scramble non-targeting sequence.

Cell Counting Kit (CCK)-8 assay. Cell viability was analyzed using a CCK-8 assay (Dojindo Molecular Technologies, Inc.). Briefly, the DU145 and PC-3 cell lines were treated with 10 µM DT061 (dissolved in DMSO) at 37˚C for 48 h, then seeded into 96-well flatbottomed microplates, at a density of 5x104 cells/well. Increasing concentrations (0, 0.05, 0.5, 1.2, 5, 200 and 500 nM) of docetaxel were subsequently added to each well and the cells were incubated at 37˚C for 48 h; each well contained a volume of 100 µl, consisting of 90 µl cell suspension and 10 µl docetaxel solution. Following incubation for 48 h at 37˚C, CCK-8 reagent was added to each well at 37˚C for 1 h and the absorbance was measured at 450 nm.

For the LNCaP cell line, the cells were first transfected with siRNA at 37˚C for 48 h, then seeded into 96-well flatbottomed microplates, at a density of 5x105 cells/well. Next, docetaxel was added to each well at gradient concentrations (0, 0.05, 0.5, 1, 2, 5, 200 and 500 nM). Following incubation at 37˚C for 48 h, CCK-8 reagent was added to each well and the cells were incubated at 37˚C for 1 h, and the absorbance was measured at 450 nm.

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from the DU145, PC-3 and LNCaP cell lines, using TRizol® (Takara Biotechnology Co., Ltd.). SYBR Green was used as the fluorophore (MedChemExpress). Total RNA was reverse transcribed into cDNA using random primers and a RT Master Mix for qPCR (gDNA digester plus), according to the manufacturer's protocol (cat. no. HY-K0511; MedChemExpress). The following thermocycling conditions were used for RT: 25˚C for 5 mins, 42˚C for 40 mins and 85˚C for 2 mins. The following thermocycling conditions were used for qPCR: Initial denaturation at 94˚C for 2 min, followed by 35 cycles at 94˚C for 40 sec, 50˚C for 40 sec and 72˚C for 1 min and final extension at 72˚C for 5 min. PP2A expression was subsequently determined using qPCR and the following primers: Human PP2A forward, 5'-AGA AGA GGA TGA ACC GTT CAC-3' and reverse, 5' -TGC TAG GCT GGA AAT CAG GG-3'; and GAPDH forward, 5'-CCTTCCGTGTCCTCCTACT-3' and reverse, 5'-GCCGTGCTTCACACCTTC-3'. GAPDH expression was used as the internal control for normalization. The 2-ΔΔCq method was used for the quantification of the expression levels (23).

Western blot analysis. Total protein was extracted from the DU145, PC-3 and LNCaP cell lines using RIPA lysis buffer (Beyotime Institute of Biotechnology) and centrifuged at 12,000 x g for 20 min at 4˚C. Total protein was quantified using a BCA protein assay kit (Beyotime Institute of Biotechnology) and 30 µg protein/lane was separated on PVDF membranes (MilliporeSigma) and blocked with 5% skimmed milk at 25˚C for 2 h. The membranes were then incubated overnight at 4˚C with the following primary antibodies: Anti-PP2A (cat. no. 12675-2-AP; dilution, 1:500), anti-XIAP (cat. no. 66800-1-Ig; dilution, 1:5,000), anti-Bax...
(cat. no. 50599-2-Ig; dilution, 1:1,000) and anti-Bcl-2
(cat. no. 12789-1-AP; dilution, 1:1,000) (all ProteinTech
Group, Inc.), anti-phosphorylated (p)-eIF4B (cat. no. R26284;
dilution, 1:5,000; Chengdu Zen Bioscience Co., Ltd),
anti-eIF4B (cat. no. R26713; dilution, 1:5,000; Chengdu Zen
Bioscience Co., Ltd), anti-GAPDH (cat. no. AB0037; dilution,
1:3,000; Shanghai Abways Biotechnology Co., Ltd.) and
anti-cleaved caspase-3 (cat. no. 9664; dilution, 1:1,000; Cell
Signaling Technology, Inc.). Following incubation with the
primary antibodies, the membranes were incubated with an
HRP-conjugated secondary antibody (cat. no. 91196; dilution,
1:2,000; Cell Signaling Technology, Inc.) at 25˚C for 1 h. The
protein bands were visualized using an ECL system (GelDoc
Go; Bio‑Rad Laboratories, Inc.). The blots were quantified
using Evolution (version number:18.0.8.0, Viber Lourmat).

Flow cytometric analysis of apoptosis. Cell apoptosis (early +
late apoptotic cells) was analyzed 48 h after treatment. LNCaP
cells were transfected with siPP2A or si-NC (5 µl; 20 µM)
at 37˚C for 6 h in the presence or absence of subsequent
5 nmol/l docetaxel treatment. DU145 and PC-3 cells were treated
with 10 µmol/l DT061 (dissolved in DMSO), 5 nmol/l
docetaxel, 10 µmol/l DT061 (dissolved in DMSO) + 5 nmol/l
docetaxel at 37˚C for 48 h; the control group was treated with
DMSO. The treated cells were subsequently trypsinized and
resuspended in PBS, then stained using reagents from the
Annexin V-FITC/PI Apoptosis Detection kit (cat. no. 556570;
BD Biosciences), according to the manufacturer's protocol.
CytoFLEX V2-B4-R0 Flow Cytometer (cat. no. C02944;
Beckman Coulter) and CytExpert software were used for
analysis (version no. 2.4.0.28; Beckman Coulter, Inc.).

Statistical analysis. All the experiments were performed three
times. Statistical analysis was performed using SPSS v22.0
software (IBM Corp.) and the data are presented as the
mean ± SD. Statistical differences between groups (unpaired)
were determined using a Student's t-test or one-way ANOVA
followed by Tukey's post hoc test. P<0.05 was considered to
indicate a statistically significant difference.

Results

PP2A expression is decreased in CRPC cells. To determine
the mRNA and protein expression level of PP2A in different
prostate cancer cell lines, including LNCaP cells (sensitive to
ADT), and the DU145 and PC-3 cells (insensitive to ADT),
RT-qPCR and western blot analysis were performed, respectivly.
The mRNA expression levels of PP2A were significantly
increased in LNCaP cells compared with those in the DU145
and PC-3 cell lines (Fig. 1A). Similarly, western blot analysis
revealed that the protein expression levels of PP2A were also
significantly increased in LNCaP cells compared with those in
the DU145 and PC-3 cell lines (Fig. 1B). These results indicated
that the expression level of PP2A was lower in AR-negative
cell lines than AR-positive cell lines.

Increase in PP2A expression promotes cell apoptosis and
drug sensitivity to docetaxel. To investigate the biological
role of PP2A in cell apoptosis and drug resistance, flow
cytometry and CCK-8 assays were performed. The small
molecule, DT061 (10 µmol/l; dissolved in DMSO), which is
able to increase the population of PP2A heterotrimers (24),
was used to upregulate PP2A expression levels in the CRPC
cell lines, DU145 and PC-3 (Fig. 2A and B). The control group
contained cells treated with DMSO. Flow cytometric analysis
of apoptosis revealed that DT061 increased the apoptosis rate
compared with the control (DMSO). Treatment with DT061
combined with docetaxel (5 nmol/l) significantly increased
the apoptotic rate compared to the Docetaxel group (5 nmol/l)
in both the DU145 and PC-3 cell lines (Fig. 2C and D). The results
of western blot analysis demonstrated that the protein
expression level of Bcl-2 was decreased in the DT061 group
compared with that in the control group, while the expression
levels of Bax and cleaved caspase-3 were increased in the
DT061 group compared with those in the control group in both
the DU145 and PC-3 cell lines (Fig. 2E and F). The results of the
CCK-8 assay found that the CRPC cell lines (DU145
and PC-3) in the DT061 group had significantly increased
sensitivity to docetaxel compared with the cell lines in the
control group (Fig. 2G and H). These results indicated that DT061 may upregulate the expression levels of PP2A, which may promote cell apoptosis and drug sensitivity to docetaxel in the CRPC cell lines.

**PP2A knockdown suppresses cell apoptosis and enhances the tolerance to docetaxel.** To further validate the role that PP2A may play in apoptosis, drug resistance and the development of prostate cancer, the LNCaP cell line was transfected with siPP2A to knock down its expression (Fig. 3A and B), then flow cytometry, western blot analysis and a CCK-8 assay were performed. Flow cytometric analysis of apoptosis found that knockdown of PP2A decreased the apoptotic rate in the LNCaP cells (Fig. 3C). The siRNA used in the transfection was siRNA2. The results of western blot analysis revealed that the expression level of Bcl-2 was increased in the siPP2A group compared with that in the si-NC group. By contrast, the expression levels of Bax and cleaved caspase-3 were decreased in the siPP2A group compared with those in the si-NC group (Fig. 3D). PP2A expression was knocked down in the LNCaP cells, which were then treated with docetaxel (0.5-500 nM) for 48 h, and cell viability was measured using a CCK-8 assay. The results demonstrated that the siPP2A group exhibited enhanced tolerance to docetaxel (Fig. 3E). These findings suggested that PP2A knockdown suppresses cell apoptosis and enhances the tolerance to docetaxel.
XIAP expression is associated with the expression level of PP2A. To determine the association between PP2A and XIAP, PP2A expression was increased or knocked down, then western blot analysis was performed to determine changes in the protein expression levels of p-eIF4B and XIAP. In the DU145 and PC-3 cell lines, when DT061 was used to increase the expression level of PP2A, the protein expression levels of p-eIF4B and XIAP were found to be significantly decreased compared with those in the si-NC group (Fig. 4A-D). By contrast, when the expression level of PP2A was knocked down in the LNCaP cells using siPP2A, the protein expression levels of p-eIF4B and XIAP were increased compared with those in the si-NC group (Fig. 4E and F). These results indicated that the change in PP2A expression may regulate the expression level of XIAP via the PP2A/eIF4B/XIAP signaling pathway.

**Discussion**

As the terminal stage of prostate cancer, CRPC has been associated with a high metastatic rate, chemotherapy resistance and poor survival rates. The median survival time of patients with CRPC was recorded as 8.6±10.6 in the Netherlands (25), 13.0 in the USA (26), 14.5 months in Italy (27). A previous study revealed that 83.8% of patients in Japan were shown to have metastases at diagnosis (28). Over the past 30 years, numerous potential drugs for CRPC have emerged, such as cabazitaxel (29,30), abiraterone acetate (31,32) and enzalutamide (33), rendering the treatment regimen of the disease more flexible and diverse. However, the curative effect of CRPC is far from satisfactory, particularly for patients with metastatic (m)CRPC (34). Significant effort has been made to improve the prognosis of these patients; however, efficient and effective therapies have not yet been developed (34). Unlike other types of cancer, such as bladder and kidney cancer, the dependence of prostate cancer on androgens for propagation and growth make it unique. Therefore, ADT is widely used in clinical practice and has been shown to be effective (35). CRPC is described as prostate cancer that has progressed despite ADT. However, to the best of our knowledge, the process through which prostate cancer cells...
become castrate-resistant is not yet completely understood. It has been suggested that ADT may inhibit the proliferation of androgen-dependent cells. This then allows androgen-independent cells to become the new dominant primary tumor cells (36). Another study has indicated that androgen receptor amplification and hypersensitivity/mutations may play a key role in this process (2). However, treatment for CRPC is difficult; therefore, it remains of utmost importance to understand the underlying mechanisms of CRPC development.
Accumulating data have demonstrated that PP2A activation is of great significance in prostate cancer. A previous study showed that PP2A activation could suppress prostate tumor growth and metastasis (37). PP2A activation inhibited the growth of androgen-independent prostate cancer cells (38). On the other hand, downregulation of PP2A enhanced metastatic ability and led to higher mortality in prostate cancer (39,40). These results indicate that PP2A activation is promising in the treatment of prostate cancer. The results of the present study found that the mRNA and protein expression levels of PP2A were decreased in prostate cancer cells, as the tumor cells transitioned from non-CRPC cells to CRPC cells. The knockdown of PP2A expression was subsequently found to promote CRPC cell chemoresistance and inhibit apoptosis. A previous study found that treatment with the PP2A activators, forskolin and FTY720, exerted antitumor effects and affected the proliferation of the PC-3 cell line (41). To determine the effect of activated PP2A on CRPC cells in the current study, the population of PP2A heterotrimers was increased by treatment with another PP2A activator, DT061 (11,24,42) in the DU145 and PC-3 cell lines. The results revealed that the CRPC cells exhibited higher apoptotic rates. In addition, the protein expression levels of the apoptosis-related proteins, Bax and cleaved caspase-3, were upregulated, while the protein expression level of Bcl-2 was downregulated. These results indicated that DT061 may regulate the expression level of apoptosis-related proteins to promote cell apoptosis. For patients with mCRPC, docetaxel remains the first-line treatment method (43). However, once resistance to docetaxel emerges, the therapeutic benefit is limited, which leads to therapeutic failure (2). In the present study, the results of the CCK-8 assay revealed that CRPC cells treated with DT061 showed an enhanced sensitivity to docetaxel. These results suggested that DT061 may ameliorate docetaxel resistance and be of potential benefit for patients with CRPC.

The functional loss of PP2A serves a key role in tumorigenesis. For example, a previous study found that protein expression levels of PP2A-Aa and PP2A-Ba are markedly decreased in breast cancer tissue and the knockdown of PP2A-Ba enhances proliferation in MCF7 breast cancer cells (44). PP2A complexes consist of structural (PP2A-A), regulatory (PP2A-B), and catalytic (PP2A-C) subunits (24). The PP2A subunits may vary in different cell lines, which may cause the PP2A protein to exhibit split bands when examined using western blot analysis. In the present study, to further investigate the roles that PP2A played in the progression of prostate cancer and its association with apoptosis and chemoresistance, siPP2A was transfected into the AR-positive cell line, LNCaP. The results revealed that the apoptotic rate was decreased following the knockdown of PP2A expression, which indicated that PP2A knockdown may play a vital role in the promotion of cell propagation. Similarly, the results of the CCK-8 assay revealed that the transfection of siPP2A into the LNCaP cell line increased the resistance of the cells to docetaxel. These results suggested that the knockdown of PP2A may decrease the curative effect of docetaxel.

The activation of PP2A has been considered as a promising therapeutic strategy in various types of cancer, including acute myeloid leukemia (45), KRAS-mutant lung cancer (46) and prostate cancer (47); however, to the best of our knowledge, the underlying mechanism of action of PP2A has not been fully determined. Previous studies revealed that a PP2A agonist increased the levels of apoptosis by downregulating cellular inhibitor of PP2A expression levels (48,49). Another study revealed that PP2A activation downregulated the phosphoproteome and weakened the stability of the androgen receptor in CRPC (50). The findings of the current study revealed that, when the expression level of PP2A was increased, the protein expression levels of p-eIF4B and XIAP were decreased. By contrast, when PP2A expression was knocked down, p-eIF4B and XIAP protein expression levels were increased. These results indicated that XIAP may be a downstream factor of PP2A and that the PP2A/p-eIF4B/XIAP signaling pathway may participate in the development of prostate cancer. There are numerous apoptosis-related pathways that are modulated or mediated by PP2A. For example, the PP2A activator, FTY720, was able to induce ferroptosis and promote multiple myeloma cell apoptosis by activating the PP2A/AMP-activated protein kinase pathway (51). In addition, PP2A was able to regulate the ERK, p38 MAPK and Akt signaling pathways to enhance apoptosis in lung cancer cells (52). However, to the best of our knowledge, whether DT061 affects these pathways remains undetermined, and further research is required to investigate the effect of PP2A activation induced by DT061. Furthermore, only in vitro not in vivo experiments were performed, which is a limitation to the present study. PP2A knockdown is known to play a key role in malignant cell proliferation and drug resistance (44). However, few studies have revealed the effect of PP2A knockdown on apoptosis and docetaxel resistance in prostate cancer. In a previous study, a longer overall survival time was observed in patients with mCRPC when treated with docetaxel compared with that in patients treated with mitoxantrone; however, docetaxel therapy was limited as a result of the emergence of tumor resistance (53). There have been numerous explanations underlying the emergence of docetaxel resistance, including the overexpression of multidrug resistance genes, tubulin alterations, the presence of androgen receptor variants and the occurrence of epithelial-mesenchymal transition (53). In the present study, XIAP protein expression levels were found to be regulated by PP2A; however, the mechanism by which the altered expression of XIAP resulted in docetaxel resistance remains unclear. A previous study found that downregulated protein expression levels of XIAP was associated with drug resistance in the DU145 cell line (54). XIAP inhibition led to an increase in caspase-3 activity and decreased cell viability, which rendered CRPC cells more sensitive to chemotherapy (54). Therefore, we hypothesized that the anti-apoptotic effect of XIAP may enhance the viability of CRPC cells and result in docetaxel resistance.

In conclusion, the findings of the current study indicated that PP2A may play a vital role in the development of CRPC. PP2A was discovered to decrease XIAP protein expression levels via the PP2A/p-eIF4B/XIAP signaling pathway, which promoted apoptosis and improved cell resistance to docetaxel. Therefore, the activation of PP2A may represent a novel therapeutic approach for the treatment of CRPC.

Acknowledgements

Not applicable.
Funding

The present study was supported by a grant from the Chongqing Basic Science and Advanced Technology Research Program (grant no. cstc2017jcyjAX0049).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

WH and SY contributed to the conception and design of the study. SY and HT performed the experiments. JZ and ZQ collected the data. JZ and ZQ confirm the authenticity of all the raw data. All authors have read and approved the first draft of the manuscript. SY, YC and HT contributed to the writing of the manuscript. SY, YC and HT contributed to the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Ritch CR and Cookson MS: Advances in the management of castration resistant prostate cancer. BMJ 355: i4405, 2016.
2. Chandrasekar T, Yang JC, Gao AC and Evans CP: Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol 4: 365-380, 2015.
3. Harris WP, Mostaghel EA, Nelson PS and Montgomery B: Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6: 76-85, 2009.
4. Pienta KJ and Bradley D: Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12: 1665-1671, 2006.
5. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM and French FS: The androgen axis in recurrent prostate cancer. Clin Cancer Res 10: 440-448, 2004.
6. Agoulnik IU and Weigel NL: Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 99: 362-372, 2006.
7. Shafi AA, Yen AE and Weigel NL: Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther 140: 223-238, 2013.
8. Grech G, Baldacchino S, Saliba C, Gritti MP, Gauci R, Petroni F, Fenech AG and Scerri C: Deregulation of the protein phosphorylase A2, PP2A in cancer: Complexity and therapeutic options. Tumour Biol 37: 11691-11700, 2016.
9. Baldacchino S, Saliba C, Petroni F, Fenech AG, Borg N and Grech G: Deregulation of the phosphatase PP2A is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther 13: 938-947, 2014.
10. Cristóbal I, Manso R, Rincón R, Caramés C, Senin C, Borroto A, Martínez-Userso J, Rodriguez M, Zazo S, Aguilera O, et al: PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther 13: 938-947, 2014.
11. Kauko O, Connor CM, Kulesskii E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, et al: PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Sci Transl Med 10: eaao1093, 2018.
12. Arrizzi E, Pippa R and Odero MD: Protein phosphatase 2A as a therapeutic target in acute myeloid leukemia. Front Oncol 6: 78, 2016.
13. Yu Y, Jin H, Xu J, Gu J, Li X, Xie Q, Huang H, Li J, Tian Z, Jiang G, et al: XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIβ mRNA stability. Int J Cancer 142: 2040-2055, 2018.
14. Mizutani Y, Nakamishi H, Li YN, Matsubara H, Yamamoto K, Sato N, Shiraishi T, Nakamura T, Mikami K, Okihara K, et al: Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol 30: 919-925, 2007.
15. Sung KW, Choi J, Hwang YK, Lee SJ, Kim HJ, Kim YJ, Cho EJ, Yoo KH and Koo HH: Overexpression of X-linked inhibitor of apoptosis protein (XIAP) is an independent unfavorable prognostic factor in childhood de novo acute myeloid leukemia. J Korean Med Sci 24: 605-613, 2009.
16. Mansouri A, Zhang Q, Ridgway LD, Tian L and Claret FX: Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol Res 13: 399-404, 2003.
17. Zhang S, Ding F, Luo A, Chen A, Yu Z, Ren S, Liu Z and Zhang L: XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol Ther 6: 973-980, 2007.
18. Ren K, Tan X, Xiao M, He W and Xiang J: Pim-2 cooperates with downstream factor XIAP to inhibit apoptosis and intensify malignant grade in prostate cancer. Pathol Oncol Res 25: 341-348, 2019.
19. Pagano MA, Tibalbi E, Molino P, Frezzato F, Trimarco V, Facci M, Zagotto G, Ribaudo G, Leanza L, Peruzzo R, et al: Mitochondrial apoptosis is induced by Alkoxyl phenyl-1-propionone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL. Leukemia 33: 1148-1160, 2019.
20. Eom T, Muslimova IA, Toskas P, Berardi V, Zhong J, Saktor TC and Tiedge H: Neuronal BC RNAs cooperate with eIF4B to mediate activity-dependent translational control. J Cell Biol 207: 237-252, 2014.
21. Ren K, Gan X, Xiao M, Wang M, Liu C, Tang Z and He W: The over-expression of Pim-2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B. Prostate 73: 1462-1469, 2013.
22. Yang J, Wang J, Chen K, Guo G, Xi R, Rothman PB, Whitten D, Zhang L, Huang S and Chen JL: eIF4B phosphorylation by pim kinases plays a critical role in cellular transformation by Abl oncogenes. Cancer Res 73: 4898-4908, 2013.
23. Li Y, Kjellund I and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
24. Leonard D, Huang W, Izadmehr S, O’Connor CM, Wirieda JD, Wang Z, Zaware N, Chen Y, Schlatter DM, Kiselar J, et al: Selective PP2A enhancement through biased heterotrimer stabilisation. Cell 181: 688-701.e16, 2020.
25. Soerjdalbie-Maikoe V, Pelger RC, Lycklama à Nijeholt GA, Arndt JW, Zwinderman AH, Bril H, Papapoulos SE and Hamdy NF: Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 31: 958-963, 2004.
26. Hwang SS, Chang VT, Alejandro Y, Mulaparthi S, Cogswell J, Arndt JW, Zwinderman AH, Bril H, Papapoulos SE and Hamdy NF: Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 31: 958-963, 2004.
27. Berruti A, Tucci M, Mosca A, Tarabuzzi R, Girlando M, cocktails to chemotherapeutics. Cancer Biol Ther 6: 978-980, 2007.
28. Inoue T, Segawa T, Kamba T, Yoshimura K, Nakamura E, et al: XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIβ mRNA stability. Int J Cancer 142: 2040-2055, 2018.
29. Kirby M, Hirst C and Crawford ED: Characterising the castration-resistant prostate cancer population: A systematic review. Int J Clin Pract 65: 1180-1192, 2011.
30. Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuysse M, Sonpavde G, North S, Albacy C, Tsao CK, et al: Randomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer. J Clin Oncol 35: 3181-3188, 2017.
31. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Struth D, Chi KN, Jones RJ, Goodman OB Jr, Saad F, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1905-2005, 2011.
32. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368: 138-148, 2013.
33. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: 1187-1197, 2012.
34. Dong L, Zieren RC, Xue W, de Reijke TM and Pienta KJ: Metastatic prostate cancer remains incurable, why? Asian J Urol 6: 26-41, 2019.
35. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et al: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373: 737-746, 2015.
36. Hoang DT, Iczkowski KA, Kilari D, See W and Nevalainen MT: Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et al: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373: 737-746, 2015.
37. Bhardwaj A, Singh S, Srivastava SK, Arora S, Hyde SJ, Andrews J, Cristóbal I, González-Alonso P, Daoud L, Solano E, Torrejón B, Manso R, Madoz-Guirpide J, Rojo F and García-Foncillas J: Activation of the tumor suppressor PP2A emerges as a potential therapeutic strategy for treating prostate cancer. Mar Drugs 13: 3276-3286, 2015.
38. Shah VM, English IA and Sears RC: Select stabilization of a tumor-suppressive PP2A heterotrimer. Trends Pharmacol Sci 41: 595-597, 2020.
39. Pandey P, Seshacharyulu P, Das S, Rachagani S, Ponnusamy MP, Vattulainen M, Sonpavde G, North S, Albany C, Tsao CK, et al: Abiraterone in metastatic prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy. Theranostics 8: 109-123, 2018.
40. Watt LF, Panicker N, Mannan A, Copeland B, Kahl RGS, Dun MD, Younger B, Roselli S and Verrills NM: Functional importance of PP2A regulatory subunit loss in breast cancer. Breast Cancer Res Treat 166: 117-131, 2017.
41. Wu SY, Wen YC, Ku CC, Yang YC, Chow JM, Yang SF, Lee WJ and Chien MH: Penfluridol triggers cytotoxic autophagy and cellular apoptosis through ROS induction and activation of the PP2A-modulated MAPK pathway in acute myeloid leukemia with different FLT3 statuses. J Biomed Sci 26: 63, 2019.
42. Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wirjedja DD, O'Connor CM, et al: Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. J Clin Invest 127: 2081-2090, 2017.
43. Zhao Z, Kurimchak A, Nikonova AS, Feiser F, Wasserman JS, Fowle H, Varughese T, Connors M, Johnson K, Makrov P, et al: PPP2R2A prostate cancer haplosufficiency is associated with worse prognosis and a high vulnerability to B55α/PP2A reconstitution that triggers centrosome destabilization. Oncogenesis 8: 72, 2019.
44. Remmerie M and Janssens V: PP2A: A promising biomarker and therapeutic target in endometrial cancer. Front Oncol 9: 462, 2019.
45. Wang J, Okkeri J, Pavic K, Wang Z, Kauko O, Halonen T, Sarek G, Ojala PM, Rao Z, Xu W and Westermarck J: Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56. EMBO Rep 18: 437-450, 2017.
46. McClintch K, Avelar RA, Cillejas D, Izadmehr S, Wirjedja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatter Z, Cooper M, et al: Small-Molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer. Cancer Res 78: 2065-2080, 2018.
47. Zhong Y, Tian F, Ma S, Wang H, Yang W, Liu Z and Liao A: FTY720 induces ferroptosis and autophagy via PP2A/AMPK pathway in multiple myeloma cells. Life Sci 260: 118077, 2020.
48. Meng G, Wang W, Chai K, Yang S, Li F and Jiang K: Combination treatment with triptolide and hydroxycamptothecin synergistically enhances apoptosis in A549 lung adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs and Akt signaling pathways. Int J Oncol 46: 1007-1017, 2015.
49. Galletti G, Leach BI, Lam L and Tagawa ST: Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev 57: 16-27, 2017.
50. Amantana A, London CA, Iversen PL and Devi GR: X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 3: 699-707, 2004.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.